Gastrointestinal side effects of drugs

Bibliography

• WYNN RL, MEILLER TF: Drugs and dry mouth. Gen. Dent. (2001) 49:10–14.
   PubMedGoogle Scholar
• APPELL RA: The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve. Clin. J. Med. (2002) 69:761–769.
   PubMed Web of Science ®Google Scholar
• DONGARI A, MCDONNELL HT, LANGLAIS RP: Drug-induced gingival overgrowth. Oral Surg. Oral Med. Oral Pathol. (1993) 76:543–548.
   PubMedGoogle Scholar
• ELLIS JS, SEYMOUR RA, STEELE JG et al.: Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J. PeridontoL (1999) 70:63–67.
   PubMed Web of Science ®Google Scholar
• FATTORE L, STABLEIN M, BREDFELDT Get al.: Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec. Care Dent. (1991) 11:107–109.
   Google Scholar
• MCGAW WT, PORTER H: Cyclosporine-induced gingival overgrowth: an ultrastructural stereologic study. Oral Surg Oral Med. Oral Pathol. (1988) 65:186–190.
   PubMedGoogle Scholar
• CECCHIN E, ZANELLO F, DE MARCHI S: Treatment of cyclosporine-induced gingival hypertrophy. Ann. Intern. Med (1997) 126:409–410.
   PubMed Web of Science ®Google Scholar
• GUGGENHEIMER J: Tetracyclines and human dentition. Compend. Contin. Educ. Dent. (1984) 5:245–254.
   PubMedGoogle Scholar
• GUGGENHEIMER J: Oral manifestations of drug therapy. Dent. Clin. North Am. (2002) 46:857–868.
   PubMedGoogle Scholar
• MOTT AE, GRUSHKA M, SESSLE BJ: Diagnosis and management of taste disorders and burning mouth syndrome.Dent. Clin. North Am. (1993) 37:33–71.
   PubMedGoogle Scholar
• POTTS AJ, HAMBURGER J, SCULLY C: The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg. Oral Med. Oral Path. (1987) 64:541–543.
   PubMedGoogle Scholar
• BEZ C, LODI G, SARDELLA A, DELLA VOLPE A, CARRASSI A: Oral lichenoid lesions after thalidomidetreatment. Dermatology (1999) 199:195.
   PubMed Web of Science ®Google Scholar
• SCULLY C, DIZ DIOS P: Orofacial effects of antiretroviral therapies. Oral Dis. (2001) 7:205–210.
   PubMed Web of Science ®Google Scholar
• MACARIO-BARREL A, TANASESCU S, COURVILLE P et al.: Mouth ulcers in patients receiving tacrolimus. Ann. DermatoL VenereoL (2001) 128:1327–1329.
   PubMedGoogle Scholar
• PALERI V, LINDSEY L: Oral ulcers caused by hydroxyurea. J. LaryngoL OtoL (2000) 114:976–977.
   PubMed Web of Science ®Google Scholar
• SCULLY C, AZUL AM, CRIGHTON A et al.: Nicorandil can induce severe oral ulceration. Oral. Surg Oral. Med. Oral. Pathol. Oral. RadioL Endod. (2001) 91:189–193.
   PubMed Web of Science ®Google Scholar
• MARQUART-ELBAZ C, LIPSKER D, GROSSHANS E, CRIBIER B: Oral ulcers induced by nicorandil: prevalence and clinicopathological aspects. Ann. DermatoL VenereoL (1999) 126:587–590.
   PubMed Web of Science ®Google Scholar
• DEMERJIAN N, BOLLA G, SPREUX A:Severe oral ulceration induced by alendronate. Clin. RheumatoL (1999) 18:349–350.
   PubMed Web of Science ®Google Scholar
• REDDING SW, HAVEMAN CW: Treating the discomfort of oral ulceration resulting from cancer chemotherapy. Compend. Contin. Educ. Dent. (1999) 20:389–396.
   PubMedGoogle Scholar
• COHEN DM, BHATTACHARYYA I, LYDIATT WM: Recalcitrant oral ulcers caused by calcium channel blockers: diagnosis and treatment considerations. J. Am. Dent. Assoc. (1999) 130:1611–1618.
   PubMed Web of Science ®Google Scholar
• COHEN DM BHATIACHARYYA I: Cinnamon-induced oral erythema multiforme-like sensitivity reaction. J. Am. Dent. Assoc. (2000) 131:929–934.
   PubMed Web of Science ®Google Scholar
• SLOMIANY BL, SLOMIANY k Aspirin ingestion impairs oral mucosal ulcer healing by inducing membrane-bound tumour necrosis factor-a release. IUBMB Lift (2000) 50:391–395.
   PubMed Web of Science ®Google Scholar
• JASPERSEN D: Drug-induced oesophageal disorders: pathogenesis, incidence, prevention and management. Drug Sal: (2000) 22:237–249.
   PubMed Web of Science ®Google Scholar
• •More than 70 drugs have been reported to induce oesophageal disorders. Taking medications without fluids or at bedtime before lying down may lead to poor oesophageal clearance of pills and mucosal irritation by the tablet.
   Google Scholar
• YAP I, GUAN R, KANG JY et ed.: Pill-induced oesophageal ulcer. Singapore Med. J. (1993) 34:257–258.
   Google Scholar
• SMITH SJ, LEE AJ, MADDIX DS, CHOW AW: Pill-induced oesophagitis caused by oral rifampicin. Ann. Pharmacother. (1999) 33:27–31.
   PubMed Web of Science ®Google Scholar
• BOTT SJ, MCCALLUM RW: Medication-induced oesophageal injury. Survey of the literature. Med. ToxicoL (1986) 1:449–457.
   PubMedGoogle Scholar
• •Drug-induced oesophagitis produces retorsternal pain, dysphagia and odynophagia. Most of these resolve with drug withdrawal. Serious complications including death are rare, but have been linked to potassium-induced oesophageal injury
   Google Scholar
• HELLER SR, FELLOWS IW, OGILVIE AL, ATKINSON M: Non-steroidal anti-inflammatory drugs and benign oesophageal stricture. Br. Med. J. (1982) 285:167–168.
   PubMed Web of Science ®Google Scholar
• •Twenty-two of 70 patients (31%) had regularly taken a NSAID before the onset of dysphagia, compared with 10 patients in a matched control group (p 0.02). The authors suggest that NSAIDs may have a causative role in the formation of oesophageal stricture and should be used with caution in patients with gastro-oesophageal reflux disease.
   Google Scholar
• KIM SL, HUNTER JG, WO JM et al: NSAIDs, aspirin and oesophageal strictures: are over-the-counter medications harmful to the oesophagus? J. Clin. Gastroenterol (1999) 29:32–34.
   Google Scholar
• WILKINS WE, RIDLEY MG, POZNIAK AL: Benign stricture of the oesophagus: role of non-steroidal anti-inflammatory drugs. Gut (1984) 25:478–480.
   PubMed Web of Science ®Google Scholar
• LONG JD, ORLANDO RC: Eicosanoids and the oesophagus. Dig. Dis. (1997) 15:145–154.
   PubMed Web of Science ®Google Scholar
• MACONI G, PORRO GB: Multiple ulcerative esophagitis caused by alendronate. Am. J. Gastroenterol (1995) 90:1889–1890.
   PubMed Web of Science ®Google Scholar
• DE GROEN PC, LUBBE DF, HIRSCH LJ et al.: Esophagitis associated with the use of alendronate. N Engl. J. Med. (1996) 335:1016–1021.
   PubMed Web of Science ®Google Scholar
• ••The authors of this study concluded thatalendronate can cause chemical oesophagitis, including severe ulceration in some patients. It was associated with swallowing alendronate with little or no water, lying down during or after ingestion of the tablet, continuing to take alendronate after the onset of symptoms, and having pre-existing oesophageal disorders.
   Google Scholar
• MARSHALL JK, RAINSFORD KD, JAMES C, HUNT RH: A randomised controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment. Pharmacol Ther. (2000) 14:1451–1457.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY: What the gastroenterologist should know about the gastrointestinal safety profile of bisphosphonates. Dig. Dis. Sci. (2002) 47:1665–1678.
   PubMed Web of Science ®Google Scholar
• ELLIOTT SN MCKNIGHT W, DAVIES NM et al.: Alendronate induces gastric injury and delays ulcer healing in rodents. Lift Sci. (1998) 62:77–91.
   PubMed Web of Science ®Google Scholar
• JONES KR, PILLSBURY HC III: Cellulose fiber diet pills. A new cause of oesophageal obstruction. Arch. Otolaryngol Head Neck Surg. (1990) 116:1091.
   PubMed Web of Science ®Google Scholar
• VAN DER VOORT PH, VAN ROON EN, GROND Al et al: Eosophageal rupture with aortic-esophageal fistula due to ingestion of foil packaged drugs. Ned Tijtischr. Geneeskd (2001) 145:1991–1994.
   PubMedGoogle Scholar
• ALLEN M, MELLOW M, ROBINSON MG, ORR WC: Comparison of calcium channel blocking agents and an anticholinergic agent on oesophageal function. Aliment. Pharmacol Ther. (1987) 1:153–159.
   PubMedGoogle Scholar
• ISHIKAWA H, IWAKIRI K, SUGIURA T, KOBAYASHI M: Effect of nifedipine administration (10 mg) on esophageal acid exposure. J. Gastroenterol. (2000) 35:43–46.
   PubMed Web of Science ®Google Scholar
• NASSAR NN, GREGG CR: Oesophageal infections. Curr. Treat. Options Gastroenterol (1998) 1:56–63.
   PubMedGoogle Scholar
• ORTUNA CORTES JA, TO VAR MARTINEZ A, RUIZ RIQUELME J et al: Esophageal candidiasis in HIV-negative patients. Rev. Esp. Enferm. Dig. (1997) 89:503–510.
   PubMedGoogle Scholar
• CHOCARRO MARTINEZ A, GALINDO TOBAL F, RUIZ-IRASTORZA G et al: Risk factors for esophageal candidiasis. Eur. J. Clin. Microbiol Infect. Dis. (2000) 19:96–100.
   PubMed Web of Science ®Google Scholar
• JONES MK, WANG H, PESKAR BM et al: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5:1418–1423.
   PubMed Web of Science ®Google Scholar
• LARKAI EN, SMITH JL, LIDSKY MD, GRAHAM DY: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am. J. Gastroenterol (1987) 82:1153–1158.
   PubMed Web of Science ®Google Scholar
• WOLFE MM, LICHTENSTEIN DR, SINGH G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl. J. Med. (1999) 340:1888–1899.
   PubMed Web of Science ®Google Scholar
• ALLISON MC, HO WATSON AG, TORRANCE CJ: Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl. J. Med. (1992) 327:749–754.
   PubMed Web of Science ®Google Scholar
• ••The intestine was examined in 713 patients post mortem. Two hundred and forty-nine patients had been prescribed NSAIDs in the 6 months before death. Gastric or duodenal ulcers were found in 21.7% of NSAID users and in 12.3% of those who had not taken NSAIDs. Small intestinal ulcers were found in 8.3% of NSAID users and in 0.3% of non-users.
   Google Scholar
• BALLINGER AB, SMITH G: COX-2 vs NSAIDs: gastrointestinal damage and prevention. Exp. Opin. Pharmacother. (2001) 2:31–40.
   PubMedGoogle Scholar
• GRAHAM DY, MALATY HM: Alendronate and naproxen are synergistic for development of gastric ulcers. Arch. Intern. Med (2001) 161:107–110.
   PubMed Web of Science ®Google Scholar
• •After 10 days of treatment in 26 healthy volunteers, gastric ulcers were present in 2 subjects (8%) receiving alendronate, 3 receiving naproxen (12%) and 10 receiving both (38%) (p 0.05 for the combination versus either drug alone).
   Google Scholar
• SAVAGE RU, MOLLER PW, BALLANTYNE CL, WELLS JE: Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drug therapy. Arthritis Rheum. (1993) 36:84–90.
   PubMed Web of Science ®Google Scholar
• •The increase in risk of peptic ulcer haemorrhage or perforation with NSAID therapy was 5.1 times the risk in controls. The odds ratio for piroxicam was 6.3, compared with 2.9 for didofenac, ketoprofen and sulindac combined.
   Google Scholar
• LANGMAN MJ, WEIL J, WAINWRIGHT P et al: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 343:1075–1078.
   PubMed Web of Science ®Google Scholar
• •The increase in risk of ulcer bleeding with NSAID use was 4.5 times the risk in controls in a population of over 60 years. Azaproprazone carried the highest risk (31.5). Risk increased with drug dose (low dose 2.5, intermediate dose 4.5, high dose 8.6).
   Google Scholar
• DE ABAJO FJ, GARCIA RODRIGUEZ LA, MONTERO D: Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population-based case-control study. Br. Med. J. (1999) 319:1106–1109.
   PubMed Web of Science ®Google Scholar
• •There was a 3-fold increased risk of upper GI bleeding in current users of SSRls. The risk was greatly increased (36.6) in patients taking NSAIDs in combination with SSRls.
   Google Scholar
• GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S, DE ABAJO FJ: Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br. J. Clin. Pharmacol (2001) 52:563–571.
   PubMed Web of Science ®Google Scholar
• HAWKEY CJ, WILSON I, NAESDAL J, LANGSTROM G, SWANNELL AJ, YEOMANS ND: Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut (2002) 51:344–350.
   PubMed Web of Science ®Google Scholar
• GARCIA RODRIGUEZ LA, HERNANDEZ-DIAZ S: Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology (2001) 12:570–576.
   PubMed Web of Science ®Google Scholar
• SIMON LS, WEAVER AL, GRAHAM DY et al.: Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. /AMA (1999) 282:1921–1928.
   PubMed Web of Science ®Google Scholar
• ••Six hundred and sixty-eight patients withRA were assigned to placebo, naproxen (500 mg b.i.d.) or various doses of celecoxib (100, 200 or 400 mg b.i.d.) for 12 weeks. The incidence of endoscopically determined gastroduodenal ulcers among patients taking celecoxib was similar to placebo (- 4%) and lower than observed with naproxen (26%).
   Google Scholar
• BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl. J. Med (2000) 343:1520–1528.
   PubMed Web of Science ®Google Scholar
• ••Eight thousand and seventy-six patientswith RA were randomised to receive either 50 mg rofecoxib or 500 mg naproxen b.i.d. At a median follow up of 9 months, significantly fewer upper clinical GI events occurred in the rofecoxib group (2.1 versus 4.5 per 100 patient-years, relative risk 0.5).
   Google Scholar
• WRIGHT JM: The double-edged sword of COX-2 selective NSAIDs. Can. Med Assoc. J. (2002) 167:1131–1137.
   PubMed Web of Science ®Google Scholar
• SMALE S, TIBBLE J, SIGTHORSSON G, BJARNASON I: Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine. Best Pract. Res. Clin. Gastroenterol. (2001) 15:723–738.
   PubMed Web of Science ®Google Scholar
• SMOGER SH, SAYED MA: Simultaneous mucosal and small bowel angioedema due to captopril. South. Med J. (1998) 91:1060–1063.
   PubMed Web of Science ®Google Scholar
• PUSPOK A, KIENER HP, OBERHUBER G: Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis. Colon Rectum (2000) 43:685–691.
   PubMed Web of Science ®Google Scholar
• •NSAID colitis is a clinically significant disease. Diagnosis is often delayed and in this study the median time from onset of symptoms to diagnosis was 1.8 years. Slow release didofenac was the most commonly involved drug.
   Google Scholar
• COX J, DANESHMEND TK, HAWKEY CJ, LOGAN RF, WALT RP: Devastating diarrhoea caused by azathioprine: management difficulty in inflammatory bowel disease. Gut (1988) 29:686–688.
   PubMed Web of Science ®Google Scholar
• ROSA I, NAHON S, COHEN C et al: Ticlopidine-induced lymphocytic colitis. Ann. Med Interne (1999)150:437–439.
   PubMedGoogle Scholar
• BAERT F, WOUTERS K, D'HAENS G et al.: Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis. Gut (1999) 45:375–381.
   Google Scholar
• PREVENTZA OA, LAZARIDES K, SAWYER MD: Ischemic colitis in young adults: a single-institution experience. J. Gastrointest. Surg-. (2001) 5:388–392.
   PubMed Web of Science ®Google Scholar
• •A retrospective review of young adults (50 years of age) diagnosed with ischaemic colitis over a period of 9 years. Fifty-two per cent (13 out of 25) of women were using oral contraceptives and 10% (4 out of 39) of all patients were taking a vasoactive drug at the time of diagnosis.
   Google Scholar
• ABLIN DS, ZIEGLER M: Ulcerative type of colitis associated with the use of high strength pancreatic enzyme supplements in cystic fibrosis. Pediatr. Radiol (1995) 25:113–115.
   PubMed Web of Science ®Google Scholar
• SMYTH RL, VAN VELZEN D, SMYTH RA et al: Strictures of the ascending colon in cystic fibrosis and high-strength pancreatic enzyme supplements. Lancet (1994) 343:85–86.
   PubMed Web of Science ®Google Scholar
• VAN VELZEN D, BALL LM, DEZFULIAN AR, SOUTHGATE A, HOWARD CV: Comparative and experimental pathology of fibrosing colonopathy. Postg-rad. Med J. (1996) 72:S39–S48.
   PubMed Web of Science ®Google Scholar
• LLOYD-STILL JD: Cystic fibrosis and colonic strictures: a new latrogenic' disease. J. Clin. Gastroenterol (1995) 21:2–5.
   PubMed Web of Science ®Google Scholar
• BANSI DS, PRICE A, RUSSELL C, SARNER M: Fibrosing colonopathy in an adult owing to overuse of pancreatic enzyme supplements. Gut (2000) 46:283–285.
   PubMed Web of Science ®Google Scholar
• VANEK VW, AL-SALTI M: Acute pseudo-obstruction of the colon (Ogilvie's syndrome). An analysis of 400 cases. Dis. Colon Rectum (1986) 29:203–210.
   Google Scholar
• LANKISCH PG, DROEGE M, GOTTESLEBEN F: Drug-induced acute pancreatitis: incidence and severity. Gut (1995) 37:565–567.
   PubMed Web of Science ®Google Scholar
• MCARTHUR KE: Drug-induced pancreatitis. Aliment. Pharmacol Ther. (1996) 10:23–27.
   PubMed Web of Science ®Google Scholar
• •Drug-induced pancreatitis is almost always acute and may be mild-to-fatal in severity. Definite proof that a drug causes pancreatitis requires that pancreatitis develops during treatment with the drug, that other likely causes of pancreatitis are not present and that pancreatitis usually recurs upon re-administration of the drug. For ethical reasons, rechallenge with the suspect drug is rarely carried out.
   Google Scholar
• RUNZI M, LAYER P: Drug-associated pancreatitis: facts and fiction. Pancreas (1996) 13:100–109.
   PubMed Web of Science ®Google Scholar
• MILMINICK T, FRICK TW: Drug-induced pancreatitis. Drug Scif (1996) 14:406–409.
   Google Scholar
• ANDERSEN V, SONNE J, ANDERSEN M: Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999. Eur. J. Clin. Pharmacol (2001) 57:517–521.
   PubMed Web of Science ®Google Scholar
• •Retrospective study of drug-induced pancreatitis made on reports to the Danish Committee on Adverse Drug Reactions. A definite relationship was stated for mesalazine, azathioprine and simvastatin on the basis of rechallenge. A possible or probable causality was considered for a further 30 drugs.
   Google Scholar
• MALLORY A, KERN F Jr: Drug-induced pancreatitis: a critical review. Gastroenterology (1980) 78:813–820.
   PubMed Web of Science ®Google Scholar